This is a working overview of alpha-MSH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The "Passover Ration" (officially called the Meal, Religious, Kosher for Passover) contains packages of Matzoh crackers and has beef, chicken (served on the bone), or salmon entrees. Each meal is in its own packet and come 12 packets to a case. For less strictly-observing servicemembers, non-certified "pork-free" menus of the regular MRE are available. The DLA offers Meal, Ready-to-Eat (MRE), Pork-Free, Individual, which consist of 12 menus selected from the regular roster of 24.
Max Bergmann (12 February 1886 – 7 November 1944) was a Jewish-German biochemist. Together with Leonidas Zervas, the discoverer of the group, they were the first to use the carboxybenzyl protecting group for the synthesis of oligopeptides.
=== Linkage isomerization === Linkage isomerism occurs with ligands with more than one donor atom, known as ambidentate ligands. For example, nitrite can coordinate through O or N. One pair of nitrite linkage isomers have structures (NH3)5CoNO2+2 (nitro isomer) and (NH3)5CoONO2+ (nitrito isomer).
== External links == ATSDR Case Studies in Environmental Medicine: Cadmium Toxicity Archived 2016-02-04 at the Wayback Machine U.S. Department of Health and Human Services CDC - Cadmium - NIOSH Workplace Safety and Health Topic U.S. Department of Health and Human Services National Pollutant Inventory - Cadmium and compounds http://www.canoshweb.org/odp/html/cadmium.htm Archived 2021-03-09 at the Wayback Machine After 'Cadmium Rice,' now 'Lead' and 'Arsenic Rice', New York Times
Sources: en.wikipedia.org
== Agricultural uses == Many sulfonylureas are used as herbicides, because they can interfere with plant biosynthesis of certain amino acids. As herbicides, sulfonylureas function by interfering with biosynthesis of the amino acids valine, isoleucine, and leucine, specifically via acetolactate synthase inhibition. Compounds in this class include amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, ethametsulfuron-methyl, cinosulfuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl-Na, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, trifloxysulfuron, triflusulfuron-methyl and tritosulfuron. These are broad-spectrum herbicides that kill plants weeds or pests by inhibiting the enzyme acetolactate synthase. In the 1960s, more than 1 kg/ha (0.89 lb/acre) crop protection chemical was typically applied, while sulfonylureates allow as little as 1% as much material to achieve the same effect.
=== Malaysia === The Malaysian Armed Forces version of the 24-hour ration pack is intended to provide one man with sufficient food and supplements for one day. Most items are domestically procured and cater to local tastes and religious dietary requirements. The ration makes extensive use of commercially available canned and dehydrated items. Wherever possible, plastic-foil pouches are used instead of cans. The ration is supplemented with precooked or freeze-dried rice. Example menu C: Beef Kurma, Chicken Masak Merah, Fish Curry, and Sambal Shrimp; Bean Curd and Vegetable mix; long bean stew; canned pineapple and canned papaya; 2 packages of quick-cooking porridge (black bean porridge and flour porridge); military biscuits; jam; instant coffee; tea; instant milk powder; sugar; salt; vitamin tablets; matches; and napkins.
Depending on the marker, it can take between 2 and 24 hours for the level to increase in the blood. Additionally, determining the levels of cardiac markers in the laboratory - like many other lab measurements - takes substantial time. Cardiac markers are therefore not useful in diagnosing a myocardial infarction in the acute phase. The clinical presentation and results from an ECG are more appropriate in the acute situation. However, in 2010, research at the Baylor College of Medicine revealed that, using diagnostic nanochips and a swab of the cheek, cardiac biomarker readings from saliva can, with the ECG readings, determine within minutes whether someone is likely to have had a heart attack.
== Expression of Draculin == As a naturally occurring anticoagulant, research into Draculin promises therapeutic strategy into new anticoagulants and provides a foundation for deeper investigations into FXa related coagulation mechanisms. Since the first step of the Draculin-FXa mechanism is driven by concentration and the second step is concentration independent, the FXa-Draculin complex behaves as irreversible under experimental conditions. Glycosylation is a common post-translational modification in which carbohydrates (glycans) are added to proteins or lipids. The resulting glycoproteins and glycolipids acquire altered physical and biochemical properties. As a glycoprotein, Draculin requires a specific glycosylation profile to express its maximum inhibitory activity. Its attached oligosaccharides are essential FXa inhibition, as demonstrated by the loss of anti-Xa activity following incubation with the lectins WGA and PNA.
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to a deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to break down glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and the nervous system. GSD-II and Danon disease are the only glycogen storage diseases characterised by a defect in lysosomal metabolism. It was first identified in 1932 by Dutch pathologist Joannes Cassianus Pompe, making it the first glycogen storage disease to be discovered.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.